ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

T-ALL Cells as Tool Cells for CAR T Therapy

Ren, Anqi; Zhao, Yuan; Zhu, Haichuan*wuhan univ sci & technol
Vaccines2023-4DOI: 10.3390/vaccines11040854
1被引7阅读
引用收藏
分享

摘要

T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic malignancy derived from T cells. Numerous CAR T therapies have been successfully applied to treat hematologic malignancies in the clinic. Nevertheless, there remain several challenges to the extensive application of CAR T cell therapy in T cell malignancies, especially in T-ALL. The main reason for CAR T therapy limitations is that T-ALL cells and normal T cells share antigens, which improves the difficulty of sorting pure T cells, resulting in product contamination, and would lead to CAR T cell fratricide. Thus, we considered creating a CAR on T-ALL tumor cells (CAR T-ALL) to prevent fratricide and eliminate tumor cells. We found that T-ALL cells transduced with CAR would actually commit fratricide. However, CAR T-ALL could kill only tumor cells on T-ALL cell lines, and other types of tumor cells had no killing function after being transferred with CAR. Furthermore, we created CD99 CAR with expression controlled by the Tet-On system on Jurkat cells, which could avoid the fratricide of CAR T-ALL during proliferation, ensuring the controllability of the killing time and effect. Jurkat transduced with a CAR-targeting antigen, which was expressed on other cancer cells, could kill other cancer cell lines, demonstrating that T-ALL cells could be used as tool cells for cancer therapy. Our study supplied a new feasible treatment regimen for cancer treatment in the clinic.

学科与关键词

关键词
immunotherapiesT-cell acute lymphoblastic leukemiaCAR TCAR Jurkat
相关
加载中…
  • CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
    Ren, Anqi; Tong, Xiqin; Xu, Na; Zhang, Tongcun; Zhou, Fuling*; Zhu, Haichuan*Vaccines, 2023, 11(1): 165.被引 7
  • Current state of CAR-T therapy for T-cell malignancies
    Luo, Liangkui; Zhou, Xuan; Zhou, Lijuan; Liang, Zhao; Yang, Jilong; Tu, Sanfang*; Li, Yuhua*Therapeutic Advances in Hematology, 2022, 13: 20406207221143025.被引 6
  • Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody
    Ye, Jing; Jia, Yujie; Tuhin, Israth Jahan; Tan, Jingwen; Monty, Masuma Akter; Xu, Nan; Kang, Liqing; Li, Minghao; Lou, Xiaoyan; Zhou, Meixia; Fang, Xiaoyan; Shao, Jiaqi; Zhu, Hongjia; Yan, Zhiqiang*; Yu, Lei*Molecular Therapy-Oncolytics, 2022, 24: 719-728.被引 10
查看全部 →

发表信息

论文状态
公开发表
期刊
Vaccines
发表日期
2023-04
卷期
第 11 卷, 第 4 期
页码
854
DOI
10.3390/vaccines11040854
成果收录
SCIE
资助标注
Natural Science Foundation of Hubei Province [2022CFB029]; National Natural Science Foundation of China [82100193]

作者

  • R

    Ren, Anqi (第一作者)

    wuhan univ sci & technol

  • Z

    Zhao, Yuan

    wuhan univ sci & technol

查看全部 3 位作者收起作者
  • Z

    Zhu, Haichuan (通讯)

    wuhan univ sci & technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417